AJK Biopharmaceuticals is a privately held biotechnology company focused on combat life–threatening infectious diseases. It is primarily focused on developing broad-spectrum antimicrobial cyclic peptides that have a low propensity for developing antimicrobial resistance (AMR).
AJK Biopharmaceuticals is conducting research and development with federal funds from the Department of Health and Human Services (HHS); National Institutes of Health (NIH), National Allergy and Infectious Diseases (NIAID) the under Grant Number: 1R41AI164997-01A1.
New antimicrobial drugs are needed to meet the urgent public health threat of antimicrobial resistance. AJK Biopharmaceutical anticipates the development and commercialization of novel antimicrobial drugs through innovative public-private partnerships and is seeking to secure both dilutive and non-dilutive financing.